ATC Group: R03BA Glucocorticoids

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of R03BA in the ATC hierarchy

Level Code Title
1 R Respiratory system
2 R03 Drugs for obstructive airway diseases
3 R03B Other drugs for obstructive airway diseases, inhalants
4 R03BA Glucocorticoids

Group R03BA contents

Code Title
R03BA01 Beclometasone
R03BA02 Budesonide
R03BA03 Flunisolide
R03BA04 Betamethasone
R03BA05 Fluticasone
R03BA06 Triamcinolone
R03BA07 Mometasone
R03BA08 Ciclesonide
R03BA09

Active ingredients in R03BA

Active Ingredient

Beclometasone is a pro-drug with weak glucocorticoid receptor binding affinity. It is extensively hydrolysed via esterase enzymes to the active metabolite beclometasone-17-monopropionate (B-17-MP), which has potent topical anti-inflammatory activity.

Betamethasone is a glucocorticoid which is about eight to ten times as active as prednisolone on a weight-for-weight basis. Betamethasone has anti-inflammatory, antipruritic, and vasoconstrictive properties.

Budesonide is a glucocorticosteroid with a high local anti-inflammatory effect. At doses clinically equivalent to systemically acting glucocorticosteroids, budesonide gives significantly less HPA axis suppression and has a lower impact on inflammatory markers.

Ciclesonide exhibits low binding affinity to the glucocorticoid-receptor. Once orally inhaled, ciclesonide is enzymatically converted in the lungs to the principal metabolite (C21-des-methylpropionyl-ciclesonide) which has a pronounced anti-inflammatory activity and is thus considered as the active metabolite.

Flunisolide is a glucocorticoid and it is several hundred times more potent than the cortisol standard. The principal mechanism of action of flunisolide is to activate glucocorticoid receptors, meaning it has an anti-inflammatory action. It is used for the treatment of allergic rhinitis.

Fluticasone has anti-inflammatory and vasoconstrictive features. Fluticasone given by inhalation at recommended doses has a potent glucocorticoid anti-inflammatory action within the lungs, resulting in a reduction of both symptoms and exacerbations of asthma, with a lower incidence and severity of adverse effects than those observed when corticosteroids are administered systemically.

Fluticasone furoate is a synthetic trifluorinated corticosteroid that possesses a very high affinity for the glucocorticoid receptor and has a potent anti-inflammatory action.

Mometasone is a topical glucocorticoid with local anti-inflammatory properties. It is likely that much of the mechanism for the effects of mometasone lies in its ability to inhibit the release of mediators of the inflammatory cascade.

Triamcinolone acetonide is a more potent derivative of triamcinolone and is approximately 8 times more potent than prednisone. Although the precise mechanism of corticosteroid anti-allergic action is unknown, corticosteroids are very effective in the treatment of allergic diseases in man. Also, local injections are thought to have an anti-inflammatory effect.

Related product monographs

Document Type Information Source  
 AIRCORT Nasal spray, suspension MPI, EU: SmPC
 ALVESCO 80 Pressurised inhalation, solution MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 ARNUITY ELLIPTA Inhalation powder MPI, US: SPL/PLR FDA, National Drug Code (US)
 ARQUIST Pressurised inhalation suspension MPI, EU: SmPC Health Products Regulatory Authority (IE)
 ASMANEX TWISTHALER Inhalation powder MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 BECLATE Nasal spray MPI, Generic Health Products Regulatory Authority (ZA)
 BECLAZONE 100mg Pressurised inhalation, solution MPI, EU: SmPC Υπουργείο Υγείας (CY)
 BECLAZONE 250mg Pressurised inhalation, solution MPI, EU: SmPC Υπουργείο Υγείας (CY)
 BECOTIDE EVOHALER Pressurised inhalation, solution MPI, EU: SmPC Health Products Regulatory Authority (IE)
 CLENIL FORTE SPRAY Pressurised inhalation solution MPI, EU: SmPC Υπουργείο Υγείας (CY)
 CLENIL Pressurised inhalation solution MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 FLIXOTIDE EVOHALER Pressurised inhalation, suspension MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 FLOVENT DISKUS Inhalation powder MPI, US: SPL/PLR FDA, National Drug Code (US)
 FRENOLYN Inhalation powder MPI, EU: SmPC Υπουργείο Υγείας (CY)
 PULMICORT TURBOHALER 100 Breath-actuated metered dose powder inhaler MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 QVAR MDI Pressurised inhalation, solution MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)
 SOPROBEC Pressurised inhalation solution MPI, EU: SmPC Medicines & Healthcare Products Regulatory Agency (GB)